Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A progressive movement disorder in a patient with multiple myeloma treated with anti-BCMA CAR-T cells that might have been related to on-target activity in the brain supports prospective neurologic monitoring after BCMA-targeting therapies.
Single-cell transcriptomic analyses of human fetal and neonatal intestinal cells reveal a subpopulation of enteroendocrine cells that produce insulin during development.
The multicenter phase 2 TRIUMPH trial shows the utility of ctDNA genotyping as a screening platform to select patients with HER2-amplified metastatic colorectal cancer who benefit from dual-HER2 blockade with trastuzumab and pertuzumab
Vaccination with BNT162b2 is associated with lower viral load in breakthrough infections of SARS-CoV-2, but this effect wanes at 2 months and vanishes at 6 months after vaccination. A third vaccine dose—or booster—restores the reduction in viral load.
This case report describes a biomarker-driven closed-loop therapy for depression using implanted electrodes to continually sense brain activity and automatically trigger direct brain electrical stimulation in high-depression states.
In an observational cohort of pregnant women in Israel, the BNT162b2 COVID-19 vaccine was found to have effectiveness similar to that seen in the general population.
In healthy adults, booster vaccination with an mRNA vaccine, irrespective of the vaccine used for the first dose, was well tolerated and elicited higher levels of spike-specific antibodies and spike-specific T cells than booster vaccination with ChAdOx1 nCov-19.
In a study of healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19, booster vaccination with BNT162b2 elicited more neutralizing antibodies with greater breadth, as well as higher frequencies of virus-specific T cells, than ChAdOx-1 nCoV-19.
Initial promise of a bacteriophage therapy for a persistent bacterial infection in an immunocompetent patient was curtailed in conjunction with a rise in phage-specific neutralizing antibodies.
New data from a large healthcare organization in Israel reveal a reduction in new infections in an unvaccinated population in communities with rapid vaccination rollouts, suggesting that mass vaccination strategies confer cross-protection of unvaccinated individuals.
A rare case of cytokine release syndrome in a patient on anti-PD-1 blockade that was likely related to BNT162b2 vaccination supports prospective monitoring of patients with cancer after COVID-19 vaccine administration.
Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals.
Post hoc analyses and follow-up of a patient with Leber congenital amaurosis treated with the antisense oligonucleotide sepofarsen as part of a clinical trial indicates sustained improvement of vision 15 months after receiving a single dose of the drug.
Breakthrough infections of SARS-CoV-2 occurring 12 or more days after the first dose of the BNT162b2 mRNA vaccine were associated with lower viral loads than those found in unvaccinated individuals, suggesting that the vaccine might reduce infectiousness.
Substitutions in SARS-CoV-2 spike protein present in the B.1.351 variant first detected in South Africa, when expressed in pseudoviruses, mediate escape from neutralization by monoclonal antibodies under clinical development and by plasma from individuals previously infected with SARS-CoV-2, but do not prevent binding of convalescent plasma to recombinant spike protein containing B.1.351 lineage substitutions.
Biallelic loss of BCMA caused a patient with multiple myeloma to relapse after anti-BCMA CAR T cell treatment. Baseline heterozygous BCMA deletions might be a risk factor for this form of resistance.
Human sera from recipients of the BNT162b2 vaccine can neutralize SARS-CoV-2 viruses containing spike mutations present in globally circulating variants of concern.
Acute mapping of responses to focal electrical neuromodulation in a patient with treatment-resistant depression reveals distinct mood and symptom changes that are highly context dependent.
A comprehensive census of the dynamics of death and regeneration of cells and tissues provides an estimation of the distribution of cellular turnover in the human body.